Hypertonic lactate for the treatment of intracranial hypertension in patients with acute brain injury.
Autor: | Bernini A; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV-Lausanne University Hospital and Faculty of Biology and Medicine, 1011, Lausanne, Switzerland., Miroz JP; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV-Lausanne University Hospital and Faculty of Biology and Medicine, 1011, Lausanne, Switzerland., Abed-Maillard S; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV-Lausanne University Hospital and Faculty of Biology and Medicine, 1011, Lausanne, Switzerland., Favre E; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV-Lausanne University Hospital and Faculty of Biology and Medicine, 1011, Lausanne, Switzerland., Iaquaniello C; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV-Lausanne University Hospital and Faculty of Biology and Medicine, 1011, Lausanne, Switzerland.; School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy., Ben-Hamouda N; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV-Lausanne University Hospital and Faculty of Biology and Medicine, 1011, Lausanne, Switzerland., Oddo M; Neuroscience Critical Care Research Group, Department of Intensive Care Medicine, CHUV-Lausanne University Hospital and Faculty of Biology and Medicine, 1011, Lausanne, Switzerland. mauro.oddo@chuv.ch.; Medical Directorate for Research, Education and Innovation, CHUV, Lausanne, Switzerland. mauro.oddo@chuv.ch. |
---|---|
Jazyk: | angličtina |
Zdroj: | Scientific reports [Sci Rep] 2022 Feb 22; Vol. 12 (1), pp. 3035. Date of Electronic Publication: 2022 Feb 22. |
DOI: | 10.1038/s41598-022-07129-z |
Abstrakt: | Hypertonic lactate (HL) is emerging as alternative treatment of intracranial hypertension following acute brain injury (ABI), but comparative studies are limited. Here, we examined the effectiveness of HL on main cerebral and systemic physiologic variables, and further compared it to that of standard hypertonic saline (HS). Retrospective cohort analysis of ABI subjects who received sequential osmotherapy with 7.5% HS followed by HL-given at equi-osmolar (2400 mOsmol/L) and isovolumic (1.5 mL/kg) bolus doses-to reduce sustained elevations of ICP (> 20 mmHg). The effect of HL on brain (intracranial pressure [ICP], brain tissue PO (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |